Savara reports improved exercise capacity in aPAP drug trial

May 18, 2026 2:55 PM

Savara Inc. (NASDAQ: SVRA) presented new exercise capacity data from its IMPALA-2 Phase 3 clinical trial of molgramostim inhalation solution ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found